Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance

Diabetes Research and Clinical Practice

Volumn 100, Issue 1, 2013, Pages 46-52

  Tsunoda, Tetsuji ^a   Nozue, Tsuyoshi ^a   Yamada, Masayo ^a   Mizuguchi, Ichiro ^a   Sasaki, Mayuko ^a   Michishita, Ichiro ^a  

^a YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

Author keywords

Diabetes mellitus; Ezetimibe; Insulin resistance; Lipoprotein

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B48; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; REMNANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; JAPAN; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84876724789     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.12.026     Document Type: Article

References (29)

1. Garg A., Grundy S.M. Management of dyslipidemia in NIDDM. Diabetes Care 1990, 13:153-169.
2. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
3. Harano Y., Miyawaki T., Nabiki J., Shibachi M., Adachi T., Ikeda M., et al. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J 2006, 53:173-180.
4. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
5. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordovas J.M., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001, 154:229-236.
6. Kugiyama K., Doi H., Takazoe K., Kawano H., Soejima H., Mizuno Y., et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999, 99:2858-2860.
7. Nozue T., Michishita I., Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 2010, 17:37-44.
8. Rizzo M., Rini G.B., Spinas G.A., Berneis K. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?. Atherosclerosis 2009, 204:330-333.
9. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
10. Deushi M., Nomura M., Kawakami A., Haraguchi M., Ito M., Okazaki M., et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007, 581:5664-5670.
11. Shimano H., Arai H., Harada-Shiba M., Ueshima H., Ohta T., Yamashita S., et al. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb 2008, 15:116-121.
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
13. Sandoval J.C., Nakagawa-Toyama Y., Masuda D., Tochino Y., Nakaoka H., Kawase R., et al. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thomb 2010, 17:914-924.
14. Kahn B.B., Flier J.S. Obesity and insulin resistance. J Clin Invest 2000, 106:473-481.
15. Boden G., Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect?. Diabetes Care 2004, 27:2253-2259.
16. Bajaj M., Suraamornkul S., Kashyap S., Cusi K., Mandarino L., DeFronzo R.A. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 2004, 89:4649-4655.
17. Masuda D., Nakagawa-Toyama Y., Nakatani K., Inagaki M., Tsubakio-Yamamoto K., Sandoval J.C., et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009, 39:689-698.
18. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
19. Videla L.A. Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. World J Hepatol 2009, 1:72-78.
20. Temel R.E., Tang W., Ma Y., Rudel L.L., Willingham M.C., Ioannou Y.A., et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007, 117:1968-1978.
21. Nomura M., Ishii H., Kawakami A., Yoshida M. Inhibition of hepatic Neiman-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009, 297:E1030-E1038.
22. Muraoka T., Aoki K., Iwasaki T., Shinoda K., Nakamura A., Aburatani H., et al. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2011, 60:617-628.
23. Park H., Shima T., Yamaguchi K., Mitsuyoshi H., Minami M., Yasui K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011, 46:101-107.
24. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
25. Keech A., Colquhoun D., Best J., Kirby A., Simes R.J., Hunt D., et al. LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose-results from the LIPID trial. Diabetes Care 2003, 26:2713-2721.
26. Rajpathak S.N., Kumbhani D.J., Crandall J., Barzilai N., Alderman M., Ridker P.M. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
27. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98:1487-1494.
28. Galeano N.F., Milne R., Marcel Y.L., Walsh M.T., Levy E., Ngu'yen T.D., et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 1994, 269:511-519.
29. Kotani K., Maekawa M., Kanno T., Kondo A., Toda N., Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1994, 1215:121-125.